Refine
Year of publication
Document Type
- Article (86)
- Preprint (2)
- Contribution to a Periodical (1)
Has Fulltext
- yes (89)
Is part of the Bibliography
- no (89)
Keywords
- inflammation (12)
- pain (8)
- macrophage (4)
- data science (3)
- endocannabinoids (3)
- neuropathic pain (3)
- prostaglandin (3)
- prostaglandins (3)
- spinal cord (3)
- Cancer (2)
- Cirrhosis (2)
- G2A (2)
- GPCR (2)
- Inflammation (2)
- IntelliCage (2)
- Liver diseases (2)
- MRP4 (2)
- Pre-analytics (2)
- animal (2)
- cytotoxicity (2)
- disease models (2)
- hyperalgesia (2)
- hyperhomocysteinemia (2)
- lipids (2)
- lipoxygenase (2)
- machine learning (2)
- macrophage polarization (2)
- macrophages (2)
- migration (2)
- mitochondria (2)
- multiple sclerosis (2)
- nociception (2)
- soluble epoxide hydrolase (2)
- tetrahydrobiopterin (2)
- vitamin B deficiency (2)
- 2-AG (1)
- 3T3-L1 mouse fibroblasts (1)
- 5-lipoxygenase (1)
- ABC transporter (1)
- ACE inhibitor (1)
- AGMO (1)
- AICAR (1)
- AMP-activated kinase (1)
- AMP-activated kinase (AMPK) (1)
- AMPK (1)
- AT1 receptor antagonist (1)
- Acquired resistance (1)
- Acute inflammation (1)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Alzheimer’s disease (1)
- Anandamide (1)
- Atherosclerosis (1)
- Autoimmune encephalomyelitis (1)
- Bayesian inference (1)
- Biomarkers (1)
- Biomarkers & Diagnostic Imaging (1)
- Blood plasma (1)
- Blood sample handling (1)
- CCL2 (1)
- CD36 (1)
- CD8+ T cells (1)
- CNDAC (1)
- CYP1A1 (1)
- CYP450 (1)
- Ceramides (1)
- Cold pain (1)
- DCK (1)
- DHA (1)
- DNA damage (1)
- DNA methylation (1)
- Data science (1)
- Diagnostic markers (1)
- EET (1)
- EPA (1)
- Eicosanoids (1)
- Endocannabinoid (1)
- Endocannabinoids (1)
- FPR (1)
- FTY720 (1)
- Fatty acids (1)
- Fatty liver (1)
- GEMs (1)
- GPR4 (1)
- GTP cyclohydrolase (1)
- Glycolysis (1)
- Glycosphingolipids (1)
- HCC marker (1)
- HDAC (1)
- HDAC4 (1)
- Heat pain (1)
- Highwire (1)
- Human experimental pain models (1)
- Intrinsic resistance (1)
- K3EDTA plasma sampling (1)
- LC-MS-based lipid mediator analysis (1)
- LC–MS/MS (1)
- Leukemia (1)
- Lipidomics (1)
- Liver (1)
- Lpar2 (1)
- Lysophosphatidic acids (1)
- MDR1 (1)
- MYCBP2 (1)
- Machine-learning (1)
- Metabolism (1)
- Metabolomics (1)
- Mitochondrial ROS (1)
- Multidrug resistance (1)
- Multiple sclerosis (1)
- NCoR1 (1)
- Neuroinflammation (1)
- Neuron (1)
- Neuronal networks (1)
- Neuroscience (1)
- Nitric oxide (1)
- Nociception (1)
- OGR1 (1)
- OPRM1 methylation (1)
- Omega lipids (1)
- Oncology (1)
- Oxidative phosphorylation (1)
- P-gp (1)
- PAM (1)
- PGE2 (1)
- PHR1 (1)
- PKA (1)
- PPARγ (1)
- PTEN inducible kinase 1 (1)
- Pain (1)
- Parkinson's disease (1)
- Peritoneal macrophages (1)
- Phospholipids (1)
- Plasma (1)
- Platelets (1)
- Portal veins (1)
- Pressure pain (1)
- Prostaglandin (1)
- Quantitative sensory testing (1)
- Rab27a (1)
- Regulatory networks (1)
- S1P (1)
- SAMHD1 (1)
- SARS-CoV-2 (1)
- SPM (1)
- Sampling protocol (1)
- Sapacitabine (1)
- Schizophrenia (1)
- Serum (1)
- Sex differences (1)
- Spinal cord (1)
- Subgroup identification (1)
- T-cell homing (1)
- T-cells (1)
- TDAG8 (1)
- TRP Channels (1)
- TRPA1 (1)
- TRPM8 (1)
- Tetrahydrobiopterin (1)
- Thrombosis (1)
- Thromboxane (1)
- Trafficking (1)
- UDP-glucose ceramide glycosyltransferase (1)
- UGCG (1)
- Ubiquitin Ligase (1)
- Veins (1)
- acetylation (1)
- acute inflammation (1)
- acute pain (1)
- adenosine receptors (1)
- adipocytes (1)
- age (1)
- alcoholic fatty liver disease (1)
- alcoholic hepatitis (1)
- alpha-synuclein (1)
- alzheimer disease (1)
- amyloid beta-peptides (1)
- analgesia (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- arachidonate 15-lipoxygenase (1)
- arachidonic acid (AA) (1)
- astrocytes (1)
- attention deficit hyperactivity disorder (1)
- autoimmune encephalomyelitis (1)
- bioactive lipids (1)
- bioactivity testing (1)
- biomarker (1)
- bipolar disorder (1)
- blood pressure (1)
- breast cancer (1)
- cAMP (1)
- cPLA2 (1)
- caloric restriction (1)
- cancer (1)
- cannabinoid receptor type 1 (1)
- cannabinoid receptors (1)
- cell barrier integrity (1)
- ceramide (1)
- ceramides (1)
- chemokine (1)
- cholesterol (1)
- chronobiology (1)
- compound screen (1)
- cortical impact (1)
- cortisol (1)
- costimulation (1)
- cyclooxygenase (1)
- cytokines (1)
- dementia (1)
- dendritic cells (1)
- desensitization (1)
- designed multitarget ligands (1)
- dorsal root ganglia (1)
- drug metabolism and distribution (1)
- drug targets (1)
- drug therapy (1)
- eNPP2 (1)
- easyPACId (1)
- eicosanoid (1)
- endoplasmic reticulum (1)
- enzyme activity assay (1)
- epigenetics (1)
- exercise (1)
- experimental pain models (1)
- fibrosarcoma (1)
- flurbiprofen (1)
- fungal sugar (1)
- gene expression (1)
- glucosylceramides (1)
- histone deacetylase (1)
- human brain (1)
- human genomics (1)
- human pain models (1)
- human pharmacology (1)
- hyperactivity (1)
- immune cells (1)
- immune system (1)
- innate immunity (1)
- interleukin-4 (1)
- inflammatory pain (1)
- learning and memory (1)
- leukocyte-endothelial cell interaction (1)
- leukotriene (1)
- lichen extracts (1)
- lipid droplets (1)
- lipidomic analysis (1)
- lipidomics (1)
- lipoxin (1)
- lipoxin A4 (1)
- lipoxygenase inhibitor (1)
- lung cancer (1)
- mPGES-1 (1)
- major depression (1)
- memory and learning tests (1)
- metabolic syndrome (1)
- metabolomics (1)
- metformin (1)
- mice (1)
- microenvironment (1)
- microglia (1)
- microlesions (1)
- mitochondrial dynamics (1)
- mitochondrial respiration (1)
- monoacylglycerol lipase (1)
- monoclonal antibody (1)
- montelukast (1)
- multidrug resistance protein 4 (1)
- natural products (1)
- next-generation sequencing (1)
- nitric oxide (1)
- nociceptors (1)
- non-alcoholic fatty liver disease (1)
- oxaliplatin (1)
- p38 MAPK (1)
- patient (1)
- perineurium (1)
- phosphatidylethanolamines (1)
- polarization (1)
- polypharmacology (1)
- post-exercise hypotension (1)
- pranlukast (1)
- progranulin (1)
- prostaglandin E (1)
- proteobacteria (1)
- proton-sensing GPCR (1)
- pruritus (1)
- quantitative sensory testing (1)
- redox signalling (1)
- resolution of inflammation (1)
- resolution of inflammation (1)
- resolvin (1)
- sEH (1)
- sciatic nerve (1)
- screening (1)
- sensory loss (1)
- sensory neurons (1)
- sensory neuropathy (1)
- simplified production (1)
- smooth muscle cells (1)
- spared nerve injury (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- sphingolipid (1)
- sphingosine-1-phosphate (1)
- sterol regulatory element binding protein-2 (1)
- tandem mass spectrometry (1)
- target variability (1)
- taste buds (1)
- transcription (1)
- traumatic brain injury (1)
- triglycerides (1)
- tumor microenvironment (1)
- tumor pain (1)
- type B (1)
- ulcerative colitis (1)
- vascular biology (1)
- xenobiotics (1)
- zafirlukast (1)
- zymosan (1)
- μ-opioid receptor regulation (1)
Institute
- Medizin (78)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (21)
- Pharmazie (12)
- Biochemie, Chemie und Pharmazie (7)
- Sonderforschungsbereiche / Forschungskollegs (5)
- Biowissenschaften (4)
- Biochemie und Chemie (2)
- Interdisziplinäres Zentrum für Neurowissenschaften Frankfurt (IZNF) (1)
- Präsidium (1)
Identifying co-expression of lipid species is challenging, but indispensable to identify novel therapeutic targets for breast cancer treatment. Lipid metabolism is often dysregulated in cancer cells, and changes in lipid metabolism affect cellular processes such as proliferation, autophagy, and tumor development. In addition to mRNA analysis of sphingolipid metabolizing enzymes, we performed liquid chromatography time-of-flight mass spectrometry analysis in three breast cancer cell lines. These breast cancer cell lines differ in estrogen receptor and G-protein coupled estrogen receptor 1 status. Our data show that sphingolipids and non-sphingolipids are strongly increased in SKBr3 cells. SKBr3 cells are estrogen receptor negative and G-protein coupled estrogen receptor 1 positive. Treatment with G15, a G-protein coupled estrogen receptor 1 antagonist, abolishes the effect of increased sphingolipid and non-sphingolipid levels in SKBr3 cells. In particular, ether lipids are expressed at much higher levels in cancer compared to normal cells and are strongly increased in SKBr3 cells. Our analysis reveals that this is accompanied by increased sphingolipid levels such as ceramide, sphingadiene-ceramide and sphingomyelin. This shows the importance of focusing on more than one lipid class when investigating molecular mechanisms in breast cancer cells. Our analysis allows unbiased screening for different lipid classes leading to identification of co-expression patterns of lipids in the context of breast cancer. Co-expression of different lipid classes could influence tumorigenic potential of breast cancer cells. Identification of co-regulated lipid species is important to achieve improved breast cancer treatment outcome.
Epigenetic control of microsomal prostaglandin E synthase-1 by HDAC-mediated recruitment of p300
(2017)
Nonsteroidal anti-inflammatory drugs are the most widely used medicine to treat pain and inflammation, and to inhibit platelet function. Understanding the expression regulation of enzymes of the prostanoid pathway is of great medical relevance. Histone acetylation crucially controls gene expression. We set out to identify the impact of histone deacetylases (HDACs) on the generation of prostanoids and examine the consequences on vascular function. HDAC inhibition (HDACi) with the pan-HDAC inhibitor, vorinostat, attenuated prostaglandin (PG)E2 generation in the murine vasculature and in human vascular smooth muscle cells. In line with this, the expression of the key enzyme for PGE2 synthesis, microsomal PGE synthase-1 (PTGES1), was reduced by HDACi. Accordingly, the relaxation to arachidonic acid was decreased after ex vivo incubation of murine vessels with HDACi. To identify the underlying mechanism, chromatin immunoprecipitation (ChIP) and ChIP-sequencing analysis were performed. These results suggest that HDACs are involved in the recruitment of the transcriptional activator p300 to the PTGES1 gene and that HDACi prevented this effect. In line with the acetyltransferase activity of p300, H3K27 acetylation was reduced after HDACi and resulted in the formation of heterochromatin in the PTGES1 gene. In conclusion, HDAC activity maintains PTGES1 expression by recruiting p300 to its gene.
Hyperhomocysteinemia has been suggested potentially to contribute to a variety of pathologies, such as Alzheimer’s disease (AD). While the impact of hyperhomocysteinemia on AD has been investigated extensively, there are scarce data on the effect of AD on hyperhomocysteinemia. The aim of this in vivo study was to investigate the kinetics of homocysteine (HCys) and homocysteic acid (HCA) and effects of AD-like pathology on the endogenous levels. The mice received a B-vitamin deficient diet for eight weeks, followed by the return to a balanced control diet for another eight weeks. Serum, urine, and brain tissues of AppNL-G-F knock-in and C57BL/6J wild type mice were analyzed for HCys and HCA using LC-MS/MS methods. Hyperhomocysteinemic levels were found in wild type and knock-in mice due to the consumption of the deficient diet for eight weeks, followed by a rapid normalization of the levels after the return to control chow. Hyperhomocysteinemic AppNL-G-F mice had significantly higher HCys in all matrices, but not HCA, compared to wild type control. Higher serum concentrations were associated with elevated levels in both the brain and in urine. Our findings confirm a significant impact of AD-like pathology on hyperhomocysteinemia in the AppNL-G-F mouse model. The immediate normalization of HCys and HCA after the supply of B-vitamins strengthens the idea of a B-vitamin intervention as a potentially preventive treatment option for HCys-related disorders such as AD.
Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis
(2017)
Bioactive lipids contribute to the pathophysiology of multiple sclerosis. Here, we show that lysophosphatidic acids (LPAs) are dysregulated in multiple sclerosis (MS) and are functionally relevant in this disease. LPAs and autotaxin, the major enzyme producing extracellular LPAs, were analyzed in serum and cerebrospinal fluid in a cross-sectional population of MS patients and were compared with respective data from mice in the experimental autoimmune encephalomyelitis (EAE) model, spontaneous EAE in TCR1640 mice, and EAE in Lpar2 -/- mice. Serum LPAs were reduced in MS and EAE whereas spinal cord LPAs in TCR1640 mice increased during the ‘symptom-free’ intervals, i.e. on resolution of inflammation during recovery hence possibly pointing to positive effects of brain LPAs during remyelination as suggested in previous studies. Peripheral LPAs mildly re-raised during relapses but further dropped in refractory relapses. The peripheral loss led to a redistribution of immune cells from the spleen to the spinal cord, suggesting defects of lymphocyte homing. In support, LPAR2 positive T-cells were reduced in EAE and the disease was intensified in Lpar2 deficient mice. Further, treatment with an LPAR2 agonist reduced clinical signs of relapsing-remitting EAE suggesting that the LPAR2 agonist partially compensated the endogenous loss of LPAs and implicating LPA signaling as a novel treatment approach.
Around 20% of the American population have chronic pain and estimates in other Western countries report similar numbers. This represents a major challenge for global health care systems. Additional problems for the treatment of chronic and persistent pain are the comparably low efficacy of existing therapies, the failure to translate effects observed in preclinical pain models to human patients and related setbacks in clinical trials from previous attempts to develop novel analgesics. Drug repurposing offers an alternative approach to identify novel analgesics as it can bypass various steps of classical drug development. In recent years, several approved drugs were attributed analgesic properties. Here, we review available data and discuss recent findings suggesting that the approved drugs minocycline, fingolimod, pioglitazone, nilotinib, telmisartan, and others, which were originally developed for the treatment of different pathologies, can have analgesic, antihyperalgesic, or neuroprotective effects in preclinical and clinical models of inflammatory or neuropathic pain. For our analysis, we subdivide the drugs into substances that can target neuroinflammation or substances that can act on peripheral sensory neurons, and highlight the proposed mechanisms. Finally, we discuss the merits and challenges of drug repurposing for the development of novel analgesics.
Background: The quantification of global DNA methylation has been established in epigenetic screening. As more practicable alternatives to the HPLC-based gold standard, the methylation analysis of CpG islands in repeatable elements (LINE-1) and the luminometric methylation assay (LUMA) of overall 5-methylcytosine content in “CCGG” recognition sites are most widely used. Both methods are applied as virtually equivalent, despite the hints that their results only partly agree. This triggered the present agreement assessments.
Results: Three different human cell types (cultured MCF7 and SHSY5Y cell lines treated with different chemical modulators of DNA methylation and whole blood drawn from pain patients and healthy volunteers) were submitted to the global DNA methylation assays employing LINE-1 or LUMA-based pyrosequencing measurements. The agreement between the two bioassays was assessed using generally accepted approaches to the statistics for laboratory method comparison studies. Although global DNA methylation levels measured by the two methods correlated, five different lines of statistical evidence consistently rejected the assumption of complete agreement. Specifically, a bias was observed between the two methods. In addition, both the magnitude and direction of bias were tissue-dependent. Interassay differences could be grouped based on Bayesian statistics, and these groups allowed in turn to re-identify the originating tissue.
Conclusions: Although providing partly correlated measurements of DNA methylation, interchangeability of the quantitative results obtained with LINE-1 and LUMA was jeopardized by a consistent bias between the results. Moreover, the present analyses strongly indicate a tissue specificity of the differences between the two methods.
Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are the leading causes of liver disease worldwide. To identify disease-specific pathomechanisms, we analyzed the lipidome, metabolome and immune cell recruitment in livers in both diseases. Mice harboring ASH or NASH had comparable disease severities regarding mortality rate, neurological behavior, expression of fibrosis marker and albumin levels. Lipid droplet size was higher in NASH than ASH and qualitative differences in the lipidome were mainly based on incorporation of diet-specific fatty acids into triglycerides, phosphatidylcholines and lysophosphatidylcholines. Metabolomic analysis showed downregulated nucleoside levels in both models. Here, the corresponding uremic metabolites were only upregulated in NASH suggesting stronger cellular senescence, which was supported by lower antioxidant levels in NASH as compared to ASH. While altered urea cycle metabolites suggest increased nitric oxide synthesis in both models, in ASH, this depended on increased L-homoarginine levels indicating a cardiovascular response mechanism. Interestingly, only in NASH were the levels of tryptophan and its anti-inflammatory metabolite kynurenine upregulated. Fittingly, high-content immunohistochemistry showed a decreased macrophage recruitment and an increased polarization towards M2-like macrophages in NASH. In conclusion, with comparable disease severity in both models, higher lipid storage, oxidative stress and tryptophan/kynurenine levels were seen in NASH, leading to distinct immune responses.
Background: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1. Methods: CNDAC was tested in 13 acute myeloid leukaemia (AML) cell lines, in 26 acute lymphoblastic leukaemia (ALL) cell lines, ten AML sublines adapted to various antileukaemic drugs, 24 single cell-derived clonal AML sublines, and primary leukaemic blasts from 24 AML patients. Moreover, 24 CNDAC-resistant sublines of the AML cell lines HL-60 and PL-21 were established. The SAMHD1 gene was disrupted using CRISPR/Cas9 and SAMHD1 depleted using RNAi, and the viral Vpx protein. Forced DCK expression was achieved by lentiviral transduction. SAMHD1 promoter methylation was determined by PCR after treatment of genomic DNA with the methylation-sensitive HpaII endonuclease. Nucleoside (analogue) triphosphate levels were determined by LC-MS/MS. CNDAC interaction with SAMHD1 was analysed by an enzymatic assay and by crystallisation. Results: Although the cytosine analogue CNDAC was anticipated to inhibit SAMHD1, SAMHD1 mediated intrinsic CNDAC resistance in leukaemia cells. Accordingly, SAMHD1 depletion increased CNDAC triphosphate (CNDAC-TP) levels and CNDAC toxicity. Enzymatic assays and crystallisation studies confirmed CNDAC-TP to be a SAMHD1 substrate. In 24 CNDAC-adapted acute myeloid leukaemia (AML) sublines, resistance was driven by DCK (catalyses initial nucleoside phosphorylation) loss. CNDAC-adapted sublines displayed cross-resistance only to other DCK substrates (e.g. cytarabine, decitabine). Cell lines adapted to drugs not affected by DCK or SAMHD1 remained CNDAC sensitive. In cytarabine-adapted AML cells, increased SAMHD1 and reduced DCK levels contributed to cytarabine and CNDAC resistance. Conclusion: Intrinsic and acquired resistance to CNDAC and related nucleoside analogues are driven by different mechanisms. The lack of cross-resistance between SAMHD1/ DCK substrates and non-substrates provides scope for next-line therapies after treatment failure.
The arachidonic acid cascade is a key player in inflammation, and numerous well-established drugs interfere with this pathway. Previous studies have suggested that simultaneous inhibition of 5-lipoxygenase (5-LO) and soluble epoxide hydrolase (sEH) results in synergistic anti-inflammatory effects. In this study, a novel prototype of a dual 5-LO/sEH inhibitor KM55 was rationally designed and synthesized. KM55 was evaluated in enzyme activity assays with recombinant enzymes. Furthermore, activity of KM55 in human whole blood and endothelial cells was investigated. KM55 potently inhibited both enzymes in vitro and attenuated the formation of leukotrienes in human whole blood. KM55 was also tested in a cell function-based assay. The compound significantly inhibited the LPS-induced adhesion of leukocytes to endothelial cells by blocking leukocyte activation.
The experience of pain is mediated by a specialized sensory system, the nociceptive system. There is considerable evidence that the cGMP/cGMP kinase I (cGKI) signaling pathway modulates the nociceptive processing within the spinal cord. However, downstream targets of cGKI in this context have not been identified to date. In this study we investigated whether cysteine-rich protein 2 (CRP2) is a downstream effector of cGKI in the spinal cord and is involved in nociceptive processing. Immunohistochemistry of the mouse spinal cord revealed that CRP2 is expressed in superficial laminae of the dorsal horn. CRP2 is colocalized with cGKI and with markers of primary afferent C fibers. Importantly, the majority of CRP2 mRNA-positive dorsal root ganglion (DRG) neurons express cGKI and CRP2 is phosphorylated in a cGMP-dependent manner. To elucidate the functional role of CRP2 in nociception, we investigated the nociceptive behavior of CRP2-deficient (CRP2-/-) mice. Touch perception and acute thermal nociception were unaltered in CRP2-/- mice. However, CRP2-/- mice showed an increased nociceptive behavior in models of persistent pain as compared to wild type mice. Intrathecal administration of cGKI activating cGMP analogs increased the nociceptive behavior in wild type but not in CRP2-/- mice, indicating that the presence of CRP2 was essential for cGMP/cGKI-mediated nociception. These data indicate that CRP2 is a new downstream effector of cGKI-mediated spinal nociceptive processing and point to an inhibitory role of CRP2 in the generation of inflammatory pain.